Literature DB >> 24522227

Core drug-drug interaction alerts for inclusion in pediatric electronic health records with computerized prescriber order entry.

Marvin B Harper1, Christopher A Longhurst, Troy L McGuire, Rod Tarrago, Bimal R Desai, Al Patterson.   

Abstract

OBJECTIVE: The study aims to develop a core set of pediatric drug-drug interaction (DDI) pairs for which electronic alerts should be presented to prescribers during the ordering process.
METHODS: A clinical decision support working group composed of Children's Hospital Association (CHA) members was developed. CHA Pharmacists and Chief Medical Information Officers participated.
RESULTS: Consensus was reached on a core set of 19 DDI pairs that should be presented to pediatric prescribers during the order process.
CONCLUSIONS: We have provided a core list of 19 high value drug pairs for electronic drug-drug interaction alerts to be recommended for inclusion as high value alerts in prescriber order entry software used with a pediatric patient population. We believe this list represents the most important pediatric drug interactions for practical implementation within computerized prescriber order entry systems.

Entities:  

Mesh:

Year:  2014        PMID: 24522227     DOI: 10.1097/PTS.0000000000000050

Source DB:  PubMed          Journal:  J Patient Saf        ISSN: 1549-8417            Impact factor:   2.844


  7 in total

1.  National trends in safety performance of electronic health record systems in children's hospitals.

Authors:  Juan D Chaparro; David C Classen; Melissa Danforth; David C Stockwell; Christopher A Longhurst
Journal:  J Am Med Inform Assoc       Date:  2017-03-01       Impact factor: 4.497

2.  The Effects of Medication Alerts on Prescriber Response in a Pediatric Hospital.

Authors:  Judith W Dexheimer; Eric S Kirkendall; Michal Kouril; Philip A Hagedorn; Thomas Minich; Leo L Duan; Monifa Mahdi; Rhonda Szczesniak; S Andrew Spooner
Journal:  Appl Clin Inform       Date:  2017-05-10       Impact factor: 2.342

3.  Prevalence of Clinically Significant Drug-Drug Interactions Across US Children's Hospitals.

Authors:  James W Antoon; Matt Hall; Alison Herndon; Alison Carroll; My-Linh Ngo; Katherine L Freundlich; Justine C Stassun; Patricia Frost; David P Johnson; Swati B Chokshi; Charlotte M Brown; Whitney L Browning; James A Feinstein; Carlos G Grijalva; Derek J Williams
Journal:  Pediatrics       Date:  2020-10-09       Impact factor: 7.124

4.  Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals.

Authors:  Dingwei Dai; James A Feinstein; Wynne Morrison; Athena F Zuppa; Chris Feudtner
Journal:  Pediatr Crit Care Med       Date:  2016-05       Impact factor: 3.624

5.  Identifying potential prescribing safety indicators related to mental health disorders and medications: A systematic review.

Authors:  Wael Y Khawagi; Douglas T Steinke; Joanne Nguyen; Richard N Keers
Journal:  PLoS One       Date:  2019-05-24       Impact factor: 3.240

6.  Structured override reasons for drug-drug interaction alerts in electronic health records.

Authors:  Adam Wright; Dustin S McEvoy; Skye Aaron; Allison B McCoy; Mary G Amato; Hyun Kim; Angela Ai; James J Cimino; Bimal R Desai; Robert El-Kareh; William Galanter; Christopher A Longhurst; Sameer Malhotra; Ryan P Radecki; Lipika Samal; Richard Schreiber; Eric Shelov; Anwar Mohammad Sirajuddin; Dean F Sittig
Journal:  J Am Med Inform Assoc       Date:  2019-10-01       Impact factor: 4.497

7.  Variation in high-priority drug-drug interaction alerts across institutions and electronic health records.

Authors:  Dustin S McEvoy; Dean F Sittig; Thu-Trang Hickman; Skye Aaron; Angela Ai; Mary Amato; David W Bauer; Gregory M Fraser; Jeremy Harper; Angela Kennemer; Michael A Krall; Christoph U Lehmann; Sameer Malhotra; Daniel R Murphy; Brandi O'Kelley; Lipika Samal; Richard Schreiber; Hardeep Singh; Eric J Thomas; Carl V Vartian; Jennifer Westmorland; Allison B McCoy; Adam Wright
Journal:  J Am Med Inform Assoc       Date:  2017-03-01       Impact factor: 4.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.